#single use bioreactor

[industryupdate]

The single-use bioreactors market, valued at USD 4.1 billion in 2024, is projected to reach USD 13.6 billion by 2030, growing at a compound annual rate of 22.0%. This surge is driven by the increasing demand for biologic and biosimilar drugs due to the rising prevalence of communicable and chronic diseases, coupled with the availability of innovative single-use bioreactors.

[health-views-updates]

Single-Use Bioreactors Market Forecast: Key Insights and Future Outlook

Single-Use Bioreactors Market Outlook, Scope & Overview:

Industry reports indicate that the global single-use bioreactors market was valued at USD 3,872.40 million in 2023 and is projected to reach USD 13,784.83 million by 2031, growing at a CAGR of 17.2% over the forecast period 2024-2031.

Technological Advancements to Drive Growth of Global Single-Use Bioreactors Market

The adoption of single-use bioreactors (SUBs) will continue to influence global market revenues. Biopharmaceutical companies and research institutions are increasingly utilizing SUBs to enhance production efficiency, reduce contamination risks, and lower manufacturing costs.

As a product segment, SUBs currently hold a significant share of the global bioprocessing market. This segment is anticipated to grow at a year-over-year rate of 17.2% in 2024 over 2023 and reach USD 13,784.83 million in revenues by 2031. The increasing demand for biologics and biosimilars, coupled with advancements in cell culture technologies, is expected to drive market growth.

Single-Use Bioreactors – Market Dynamics

Drivers:

Single-use bioreactors are witnessing significant growth in the global market due to their ability to provide flexibility, scalability, and cost-effectiveness in biopharmaceutical production. The growing focus on reducing the risk of cross-contamination, the need for efficient process development, and the increasing adoption of disposable technologies in bioprocessing are key factors driving the adoption of SUBs worldwide. Additionally, the rising demand for personalized medicine and regenerative therapies is further propelling market growth.

Restraints:

Despite the growth potential, challenges such as high initial costs, concerns about the environmental impact of disposable systems, and the need for robust validation processes are hindering the widespread adoption of single-use bioreactors. Moreover, the limitations in handling large-scale production and the technical challenges associated with integrating SUBs into existing bioprocessing workflows pose additional challenges to market expansion.

Single-Use Bioreactors – Market Outlook

The proven benefits of single-use bioreactors in enhancing production efficiency, reducing operational costs, and improving process control have contributed to the market's growth. SUBs are expected to witness increased adoption across major biopharmaceutical markets, including North America, Europe, and Asia Pacific, driven by advancements in biotechnology and the growing focus on bioprocess optimization.

Global Single-Use Bioreactors Market

The rise in demand for single-use bioreactors in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global SUB market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of single-use bioreactors, supported by favorable regulatory frameworks and increasing investments in biopharmaceutical manufacturing.

Key Players in the Single-Use Bioreactors Market

Leading companies in the single-use bioreactors market include Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, and Merck KGaA. These companies are at the forefront of developing and commercializing advanced single-use bioreactor systems for various bioprocessing applications, including cell culture, fermentation, and vaccine production.

In conclusion, the global single-use bioreactors market is poised for substantial growth over the forecast period, driven by technological advancements, increasing demand for biologics, and the expanding adoption of disposable bioprocessing solutions in biopharmaceutical production.

Other Trending Reports

Antibiotics Market Share by Company

Healthcare Business Intelligence (BI) Market Share by Company

Clinical Trial Imaging Market Share by Company

Proteomics Market Share by Company

[mitalipingale]

The Single Use Bioreactors Market in 2023 is US$ 5.05 billion, and is expected to reach US$ 24.47 billion by 2031 at a CAGR of 21.80%.

[market-insider]

Single-Use Bioprocessing Market in the Quest for Efficient Biopharmaceutical Production

The global single-use bioprocessing market size is projected to reach USD 80.13 million by 2030, registering a compound annual growth rate (CAGR) of 16.24% over the forecast period, according to a new report by Grand View Research, Inc. The demand for single-use bioprocessing offerings is driven by the commercial advantages offered, including a reduction in costs and time required for bioprocessing operations. Originally used for monoclonal antibody production, single-use technologies are also gaining traction for cell and gene therapy manufacturing. As a result, broadening the scope of applications in biomanufacturing operations is likely to drive industry growth.

Single-use Bioprocessing Market Report Highlights

The simple & peripheral elements segment held the largest share in 2023 due to the significant adoption of these products as a result of a variety of customizable options available for bioprocessing applications

The upstream bioprocessing workflow segment accounted for the largest share in 2023. Continuous developments and betterment in technologies for upstream bioprocessing are driving the segment growth

North America was the leading region in 2023 due to the high R&D spending and growth of the biopharmaceutical manufacturing sector in the region

Furthermore, the presence of key players, such as Thermo Fisher Scientific, Inc. and Danaher Corp., is driving the regional market

The biopharmaceutical manufacturers end-use segment dominated the industry in 2023 and accounted for the maximum revenue share. This was due to the high demand for biologics and heavy investments in cell & gene therapy manufacturing

For More Details or Sample Copy please visit link @: Single-use Bioprocessing Market Report

Furthermore, strategic initiatives from key players are expanding the industry's growth prospects. For instance, in July 2021, Cytiva and Pall Corp. announced investment plans for capacity expansion over two years. Among other key products, more than USD 300 million were invested in single-use technologies, such as bioreactor bags for cell expansion, used to make personalized therapies and syringe filters for scientific research. Similarly, the growing adoption of single-use equipment for in-house and contract manufacturing has opened new avenues for the flow of investments in this space. The industry is witnessing significant advancements in several product portfolios, including disposable probes and sensors, stirring systems, bioreactor designs, and filtration technologies, which are expected to contribute to strong revenue growth.

The benefits offered by single-use bioprocessing systems have enabled biopharmaceutical manufacturers to offer their products faster to the market by introducing multi-product facilities, entering into partnerships, or outsourcing pipeline products for contract development and manufacturing. For instance, in January 2021, Sartorius AG partnered with RoosterBio, a leading supplier of human Mesenchymal Stem/Stromal Cells (hMSC). This collaboration aimed at advancing cell & gene therapy manufacturing by leveraging the single-use manufacturing technologies from Sartorius AG. The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry.

[andmaybegayer]

latest Freddie DeBoer seems odd. It's very focused on a sort of consumer-facing understanding of technology for a lot of its runtime. He's not wrong that the changes are smaller than they were in the 1800's but like. That's the low hanging fruit, we all know this, the jump from "not having trains" to "having trains" beats almost any improvement in "trains"

A major change technology has brought to the modern world imo is heavily streamlined manufacturing all across the industrial stack.

If you read like, Bunie Huang's Made in China blog series, in the early 2000's getting a piece of technology made required enormous in-person investment of time and effort working with your manufacturing teams across a pretty broad number of suppliers and industries, you had to get PCB's made, components sourced, moulds designed and set up for injection.

I know people manufacturing small to medium run commercial and industrial electronics, and I did that at my last job. You order machine populated PCB's from your favourite Chinese PCB solutions provider over a web form. If you need ten thousand buttons, you can get that delivered with three emails. Hell, if you want a custom genome to use for some experimental bioreactor, there's multiple competing suppliers who will mail you plasmids that you can customise from online templates and you don't even have to talk to anyone.

And that's just mass manufacturing. If you're making a few thousand of some high end medical equipment, or still in the development phase of design, you can order a titanium laser print to be delivered by the end of the week, or run off a dozen prototypes on your company's fleet of printers using body safe plastics.

Consumer needs don't change much because people are people, we have limited capacity to need things and do things. I've long said that no human can digest more than 50Mbps of media in real time, really. One home cook can only economise their movements so much. A food processor and a pressure cooker can save you some time but the solution to"I want to spend less time cooking at home" will eventually become "don't cook at home, lean on industrial manufacturing of food" and that's fine. There's only so much tech can improve your individual experience before you become the bottleneck.

Faster computers sure, means you can edit video on your phone a little quicker (also hey people ARE editing video on their phone, despite what this blog post says) but it also means Netflix can serve their 4 Petabytes of video library at 400+Gbps from a single server occupying less than 50 liters of space.

It seems disingenuous to act like consumer products feeling stagnant means technology is stagnant.

[hello-delicious-tea]

Apparently Serbia, and especially Belgrade, has a huge problem with air pollution.

Ms. Francine Pickup, Resident Representative of the United Nations Development Program (UNDP) in Serbia, explained that: “It is estimated that cities are the source of as much as 75% of total CO2 emissions in the world, of which the largest percentage comes from traffic and cooling and heating in buildings”. She later continued to explain that 59% of the Serbian population lives in urban areas and that the number is constantly increasing. Because the population density is so high, creating green areas and planting trees – which represent natural air purification in urban areas– is a complex goal to achieve, as there is a lack of free areas for landscaping.

The microalgae replace two 10-year-old trees or 200 square meters of lawn. The function of the LIQUID 3 is practically an imitation of it. Both trees and grass perform photosynthesis and bind carbon dioxide. However, the advantage of microalgae is that it is 10 to 50 times more efficient than trees. The team behind LIQUID 3 has stated that their goal is not to replace forests or tree planting plans but to use this system to fill those urban pockets where there is no space for planting trees. In conditions of intense pollution, such as Belgrade, many trees cannot survive, while algae do not have a problem with the great levels of pollution.

The project is designed to be multifunctional. LIQUID3 is also a bench, it has chargers for mobile phones, as well as a solar panel, thanks to which the bench has lighting during the night.

Dr. Ivan Spasojevic also explained that “the Institute used single-celled freshwater algae, which exist in ponds and lakes in Serbia and can grow in tap water, and are resistant to high and low temperatures. The system does not require special maintenance – it is enough to remove the biomass created by dividing algae, which can be used as an excellent fertilizer, in a month and a half, pour new water and minerals, and the algae continue to grow indefinitely. This project aims to popularize and expand the use of microalgae in Serbia, because they can be used in wastewater treatment, as compost for green areas, for the production of biomass and biofuels, as well as for air purification from exhaust gases from the factories”.

[insightfulblogz]

Single-use Bioprocessing Market Outlook, Size, Growth, Price, Latest Trends & Industry Forecast 2032

Single-use Bioprocessing 2024

Single-use bioprocessing is a modern innovation that is transforming the landscape of pharmaceutical manufacturing and biotechnological production. Traditionally, bioprocessing involves the use of reusable equipment such as bioreactors and filtration systems, which require extensive cleaning and sterilization between uses. However, the advent of single-use bioprocessing has introduced an alternative that simplifies and accelerates the manufacturing process, reducing the need for cleaning, sanitization, and validation. This shift toward disposable systems has brought substantial efficiency gains, cost savings, and reduced time to market for pharmaceutical products.

Single-use Bioprocessing Market was estimated at USD 27.99 billion in 2023 and is expected to reach USD 108.19 billion by 2032 with a growing CAGR of 16.21% during the forecast period of 2024-2032.

Benefits of Single-Use Bioprocessing

Single-use bioprocessing offers several key advantages over traditional, reusable systems. One of the primary benefits is the reduction in cross-contamination risks, as disposable equipment is used for a single batch and then discarded. This eliminates the labor-intensive cleaning processes required for multi-use systems, lowering operational costs and reducing the potential for human error during the cleaning and sterilization procedures.

The flexibility offered by single-use systems is another significant advantage. These systems can be rapidly deployed, allowing manufacturers to scale production up or down with ease depending on demand. Unlike stainless-steel equipment, which requires significant time and resources for assembly, single-use systems can be set up and replaced quickly. This flexibility is particularly beneficial for small-scale, high-mix production environments or when producing rare or specialty drugs.

Furthermore, single-use bioprocessing systems offer significant advantages in terms of reducing the environmental impact of pharmaceutical production. Traditional systems often require large quantities of water, detergents, and chemicals for cleaning. In contrast, the disposable nature of single-use components means that fewer cleaning agents and less water are needed, leading to a more sustainable process.

Applications in Biopharmaceutical Manufacturing

In biopharmaceutical manufacturing, single-use systems have become crucial for the production of biologics, vaccines, and gene therapies. These therapies often require precision in every step of the manufacturing process, from cell culture to protein purification. With single-use bioreactors, manufacturers can streamline the cell culture process, improving cell growth and product yield while reducing contamination risks. As biologics become more prevalent, the demand for such systems has grown, further driving the need for single-use technologies in production lines.

In addition to cell culture, single-use bioprocessing is also widely used for filtration, mixing, and storage applications. Filtration systems, for example, are critical in the separation of proteins, viruses, and other by-products from the final product. Single-use filters provide an efficient, contamination-free alternative to traditional reusable filtration equipment, further enhancing the production process.

The modularity of single-use systems also offers advantages in the flexibility of scaling up or down depending on the specific production needs. For companies looking to launch new drugs or therapies, single-use systems allow for easier setup and quicker production cycles. This ability to scale production with minimal investment in new equipment is a major reason why many biopharmaceutical companies are making the shift to single-use technologies.

Challenges and Limitations

While single-use bioprocessing offers many benefits, it is not without its challenges. One key concern is the management of waste. Given that single-use systems are disposed of after each use, this can lead to significant increases in the amount of plastic waste generated. Biopharmaceutical companies are actively seeking sustainable solutions, such as using biodegradable or recyclable materials in the design of disposable components to address this issue.

Another challenge is the upfront cost of transitioning from traditional systems to single-use technologies. While single-use components often result in cost savings over time, the initial investment in these technologies can be high. Companies may also need to invest in training staff and adapting their facilities to accommodate the new systems.

Despite these challenges, the overall benefits of single-use bioprocessing, particularly in terms of efficiency, scalability, and reduced risk of contamination, continue to drive adoption across the pharmaceutical industry.

The Future of Single-Use Bioprocessing

The future of single-use bioprocessing is bright, with continued innovation expected in areas such as system integration, automation, and sustainability. As the demand for biologics and personalized medicines grows, the need for more adaptable and efficient manufacturing processes will only increase. Single-use technologies are poised to meet these demands, providing manufacturers with the tools they need to stay competitive and responsive in an ever-evolving market.

In addition, advancements in materials science and engineering will likely lead to the development of more sustainable and cost-effective disposable components, helping to mitigate environmental concerns. The ongoing development of closed-system technologies, which help prevent contamination by minimizing human intervention, is another area of significant progress.

As the biopharmaceutical industry continues to evolve, single-use bioprocessing will undoubtedly play an increasingly critical role in shaping the future of drug manufacturing, offering solutions that meet both the demands of efficiency and sustainability.

Conclusion

Single-use bioprocessing is revolutionizing the pharmaceutical manufacturing landscape by offering a more efficient, cost-effective, and flexible approach to production. With growing applications in biologics, vaccines, and gene therapies, this technology is enabling faster, cleaner, and more scalable manufacturing processes. Despite some challenges, including waste management and upfront costs, the benefits of single-use systems are clear. As the industry moves toward more sustainable practices, the future of single-use bioprocessing looks increasingly promising, paving the way for innovations in drug production and healthcare delivery.

Get Free Sample Copy @ https://www.snsinsider.com/sample-request/3661

Contact Us:

Akash Anand – Head of Business Development & Strategy

info@snsinsider.com

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

About Us

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

[healthcaremarketanalysis]

Exploring the Single-Use Bioprocessing Market: Trends, Benefits, and Future Opportunities

The Single-Use Bioprocessing Market has emerged as a transformative segment in the biopharmaceutical industry. With increasing demand for flexible, efficient, and cost-effective bioprocessing solutions, single-use systems (SUS) are becoming the cornerstone of modern biomanufacturing. This blog delves into the key aspects of the single-use bioprocessing market, its benefits, trends, and future opportunities.

Download PDF Brochure

What is Single-Use Bioprocessing?

Single-use bioprocessing refers to the use of disposable bioprocessing equipment and components made from polymers or plastics. These systems are designed for single-use, eliminating the need for cleaning and sterilization. Typical single-use bioprocessing components include:

Bioreactors

Mixing systems

Filtration assemblies

Storage bags

Tubing and connectors

These disposable technologies cater to small-scale and large-scale biopharmaceutical production.

Market Drivers for Single-Use Bioprocessing

The increasing adoption of single-use systems is driven by several factors:

1. Cost-Effectiveness

Single-use systems significantly reduce costs associated with cleaning, sterilization, and validation. Traditional stainless-steel equipment requires extensive maintenance and validation, which SUS eliminate.

2. Flexibility

Single-use systems offer unmatched flexibility. They allow manufacturers to switch between products quickly, enabling faster production of biologics and reducing time-to-market.

3. Scalability

Single-use technologies are ideal for clinical and commercial-scale production, particularly for biologics, cell therapies, and vaccines.

4. Reduced Contamination Risk

Since SUS are pre-sterilized and disposable, they minimize contamination risks, ensuring product integrity and compliance with stringent regulatory requirements.

Request Sample Pages

Applications of Single-Use Bioprocessing

Single-use systems are widely used across various stages of biomanufacturing:

1. Upstream Processing

Single-use bioreactors dominate upstream processing due to their scalability and ease of use. They are commonly used for culturing cells and producing biologics.

2. Downstream Processing

Single-use systems for downstream processing include filtration units and chromatography columns, streamlining purification processes.

3. Vaccine Production

The COVID-19 pandemic highlighted the need for rapid vaccine development. Single-use technologies played a critical role in scaling up vaccine production.

4. Cell and Gene Therapies

The precision and flexibility of SUS make them indispensable in the manufacture of personalized cell and gene therapies.

Emerging Trends in the Single-Use Bioprocessing Market

The single-use bioprocessing market is continuously evolving, driven by technological innovations and changing industry demands. Key trends include:

1. Automation and Digitalization

The integration of sensors, IoT, and AI into single-use systems enhances process monitoring, data collection, and analytics, improving efficiency and quality control.

2. Sustainability Initiatives

With increasing focus on sustainability, manufacturers are developing recyclable or biodegradable single-use components to address environmental concerns.

3. Expansion in Emerging Markets

The adoption of single-use systems is gaining traction in emerging markets like Asia-Pacific, driven by the region's growing biopharmaceutical manufacturing capabilities.

4. Modular Bioprocessing

Modular bioprocessing facilities, equipped with single-use technologies, are being designed to meet diverse production needs and enable rapid deployment.

Challenges in the Single-Use Bioprocessing Market

While single-use systems offer numerous benefits, they also face certain challenges:

1. Plastic Waste Management

The disposable nature of single-use systems generates significant plastic waste, raising concerns about environmental impact.

2. Supply Chain Constraints

The growing demand for SUS has led to supply chain bottlenecks, impacting timely availability of components.

3. Compatibility Issues

Ensuring compatibility between different single-use components and systems remains a technical challenge.

Future Opportunities

The future of the single-use bioprocessing market is bright, with ample opportunities for growth:

1. Advancements in Materials

Innovations in biocompatible and sustainable materials will address concerns related to waste and environmental impact.

2. Integration with Continuous Manufacturing

Single-use systems are being integrated into continuous manufacturing processes, enhancing productivity and reducing costs.

3. Expansion in Biosimilars

As the biosimilars market grows, single-use technologies will play a crucial role in cost-efficient production.

Market Insights

Key Players

Leading companies in the single-use bioprocessing market include:

Thermo Fisher Scientific

Sartorius AG

Merck KGaA

Danaher Corporation

GE Healthcare

Market Size and Growth

The global single-use bioprocessing market is expected to witness robust growth, driven by increasing biopharmaceutical R&D investments and demand for biologics.

Conclusion

The Single-Use Bioprocessing Market is revolutionizing biopharmaceutical manufacturing. Its ability to enhance efficiency, reduce costs, and ensure product safety positions it as a vital technology for the future of biologics production. As the industry evolves, innovations in materials, digitalization, and sustainable practices will further bolster the adoption of single-use systems. Biomanufacturers and stakeholders must navigate challenges while leveraging the immense opportunities this market presents.

By embracing single-use bioprocessing, the biopharmaceutical industry can continue to meet the growing global demand for biologics, vaccines, and advanced therapies efficiently and sustainably.

Content Source:

[mitalipingale]

https://tannda.net/read-blog/68852_single-use-bioreactors-market-size-overview-share-and-forecast-2031.html

The Single Use Bioreactors Market in 2023 is US$ 5.05 billion, and is expected to reach US$ 24.47 billion by 2031 at a CAGR of 21.80%.